

Media Release

Zug, 3 January 2014

HBM Healthcare Investments achieves compelling value increase of 65 percent in the calendar year 2013

The net asset value per share (NAV) of HBM Healthcare Investments rose by 10 percent during the quarter just ended to CHF 95.50 as at 31 December 2013. The share price increased by 2 percent, to close the quarter at CHF 66.25.

Including the par value repayment of CHF 1.50 per share, the NAV gained 65 percent in the calendar year 2013. The share price rose by 46 percent during the same period. This compares as follows to the performance of different stock indices (total return, in CHF): MSCI World Healthcare Index +33%, Swiss Market Index (SMI) +24%, Swiss Performance Index (SPI) +28%, Dow Jones Industrial Average Index +25%, Euro Stoxx 50 Index +24%.

On the basis of the year-end NAV, HBM Healthcare Investments expects to report a consolidated profit of over CHF 240 million for the first nine months of the current financial year. A consolidated loss of CHF 16 million was generated during the corresponding period of the prior year.

Pleasant value increases were observed for various holdings. The largest contributions to the result for the first nine months came from the investments in Basilea Pharmaceutica (CHF +101 million, share price +92%), Ophthotech Corporation (CHF +82 million, share price +525%), Pacira Pharmaceuticals (CHF +42 million, share price +99%), SkyePharma (CHF +19 million from equity and bond investment, share price +142%), ChemoCentryx (CHF -13 millionen, share price -58%), Enanta Pharmaceuticals (CHF +9 millionen, share price +50%) und PTC Therapeutics (CHF +8 millionen, share price +41%).

The presented figures are preliminary results, based on the current status of work on the closing of the financial statements. The final result will be published on 31 January 2014 with the quarterly report as at end of December 2013.

For further information, please contact Dr. Andreas Wicki, tel.: +41 41 768 11 08, andreas.wicki@hbmhealthcare.com

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare Investments

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of some twenty five promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of development. The focus of investment is on follow-on financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM Healthcare Investments Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | info@hbmhealthcare.com
www.hbmhealthcare.com